Table 4. Effect of preincubation with L-NAME (0.1 mmol/L), 7-nitroindazol (7-NI, 0.1 mmol/L), loratadine 7-NI, 1 mmol/L loratadine, 1 mmol/L famotidine or 0.1 mmol/L TTX on basal and EFS-induced NO release in control, ketotifen-incubated (0.1 mmol/L) and tranilast-incubated (0.1 mmol/L) mesenteric segments.
| Basal | EFS | |
|---|---|---|
| Control | 0.28 + 0.05 | 0.95 + 0.09* |
| L-NAME | 0.26 + 0.04 | 0.29 + 0.07# |
| 7-NI | 0.27 + 0.09 | 0.31 + 0.06# |
| Loratadine | 0.32 + 0.07 | 0.92 + 0.13* |
| Famotidine | 0.27 + 0.12 | 0.94 + 0.17* |
| TTX | 0.25 + 0.03 | 0.28 + 0.11# |
| Ketotifen | 0.07 + 0.01 | 0.23 + 0.11* |
| L-NAME | 0.05 + 0.03 | 0.07 + 0.04# |
| 7-NI | 0.09 + 0.04 | 0.11 + 0.04# |
| TTX | 0.06 + 0.03 | 0.07 + 0.03# |
| Tranilast | 0.07 + 0.02 | 0.38 + 0.16* |
| L-NAME | 0.06 + 0.01 | 0.09 + 0.04# |
| 7-NI | 0.06 + 0.02 | 0.08 + 0.03# |
| TTX | 0.04 + 0.01 | 0.04 + 0.01# |
Results (means ± S.E.M.) are expressed in arbitrary units (A.U.)/mg tissue. n = 6-10 animals each group. *P < 0.05 compared with the respective basal NO release. #P < 0.05 compared with conditions without specific inhibitor.